Algernon Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Algernon Pharmaceuticals hat ein Gesamteigenkapital von CA$2.0M und eine Gesamtverschuldung von CA$0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen CA$3.9M bzw. CA$1.9M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

CA$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	CA$609.52k
Eigenkapital	CA$1.96m
Gesamtverbindlichkeiten	CA$1.93m
Gesamtvermögen	CA$3.89m

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: AGNP.FDie kurzfristigen Aktiva des Unternehmens (CA$687.0K) decken seine kurzfristigen Passiva (CA$1.9M) nicht.

Langfristige Verbindlichkeiten: AGNP.F hat keine langfristigen Verbindlichkeiten.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: AGNP.F ist schuldenfrei.

Schulden abbauen: AGNP.F hat in den letzten 5 Jahren keine Schulden gemacht.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: AGNP.F verfügt auf der Grundlage des zuletzt gemeldeten freien Cashflows über eine ausreichende Liquiditätsreserve für 3 Monate. [freien Cashflow]], hat aber seitdem zusätzliches Kapital aufgenommen.

Vorhersage Cash Runway: Es wird prognostiziert, dass AGNP.F auf Grundlage der Schätzungen des freien Cashflows über ausreichend Liquidität für 3 Monate verfügt, das Unternehmen hat seitdem jedoch weiteres Kapital aufgenommen.

Algernon Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

Algernon Pharmaceuticals Inc. announced that it has received CAD 0.2352 million in funding

Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.15 million in funding

Algernon Pharmaceuticals Inc. announced that it has received CAD 0.408 million in funding

Algernon Pharmaceuticals Inc. Reports Results of Study Showing 93% Cough Suppression with Ifenprodil

Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.25 million in funding

Algernon Pharmaceuticals Inc., Annual General Meeting, Jul 10, 2024

Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset

Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis

Algernon Pharmaceuticals Inc. announced that it has received CAD 0.28 million in funding

Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.15 million in funding

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.205 million in funding

Algernon Pharmaceuticals Inc. Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

Algernon Pharmaceuticals Inc. Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil

Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

Algernon Pharmaceuticals Inc. Enters into A Clinical Trial Agreement with Yale University for A DMT Phase 2 Depression Study

Algernon Pharmaceuticals Files for Orphan Designation with the U.S. Fda for Ifenprodil as A Treatment of IPF

Algernon Pharmaceuticals Inc. Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

Algernon Pharmaceuticals Inc. Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

Algernon Pharmaceuticals Inc. announced that it has received funding from AlphaNorth Asset Management

Algernon Pharmaceuticals Inc. announced that it has received CAD 1.402125 million in funding

Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 1.402125 million in funding

Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 1.402125 million in funding

Algernon Pharmaceuticals Reports Additional Positive Data from Its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

Algernon Pharmaceuticals Hits Co-Primary Endpoint in Its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

Algernon Pharmaceuticals Inc. Provides Update on Its Planned Phase 1 Repirinast Chronic Kidney Disease Study

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

Algernon Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 1.159189 million.

Algernon Pharmaceuticals Inc. Announces Patients Requested Ongoing Supply of Ifenprodil After IPF and Chronic Cough Phase 2 Study Ended

Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough

Algernon Pharmaceuticals Inc. Announces Last Patient Treated in Phase 2 Study of IPF and Chronic Cough

Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH Study

Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program

Algernon Pharmaceuticals Announces Completion of Enrollment in Its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

Algernon Pharmaceuticals Inc., Annual General Meeting, Feb 28, 2022

Algernon Pharmaceuticals Inc., Annual General Meeting, Feb 28, 2022

Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of Its Psychedelic Drug Dmt Intellectual Property

Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study

Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial

Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study

Algernon Pharmaceuticals Inc. Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Small Cell Lung Cancer Study

Algernon Pharmaceuticals Inc. Plans to File Pre-Investigational New Drug Meeting Request with U.S. Food and Drug Administration for NP-120 (Ifenprodil) Phase 2 Chronic Cough Study

Algernon Pharmaceuticals Announces Small Cell Lung Cancer Ifenprodil Research Program

Algernon Pharmaceuticals Inc. Targets First Human Study of Its Psychedelic Drug DMT Stroke Program for fourth quarter of 2021

Algernon Pharmaceuticals Inc. Launches Pancreatic Cancer Clinical Research Program with Ifenprodil

Algernon Pharmaceuticals Inc. Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke

Algernon Pharmaceuticals Inc. Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke

Algernon Pharmaceuticals Inc. Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study

Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

Algernon Pharmaceuticals Inc. Files End of Phase 2 Meeting Request with U.S. FDA for Its Covid-19 Trial of Ifenprodil

Algernon Pharmaceuticals Inc. Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

Algernon Pharmaceuticals Inc. Provides Update on Timing of Topline Results for Phase 2B/3 Covid-19 Trial of Ifenprodil

Algernon Pharmaceuticals Inc. announced that it has received CAD 2.81501 million in funding

Algernon Pharmaceuticals Announces Management Changes

Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data

Algernon Pharmaceuticals Inc. Considers Adding Lung Scarring as an Additional Endpoint for Its Phase 2B/3 Covid-19 Study Protocol

Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT The Spirit Molecule

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen